Format

Send to

Choose Destination
J Pediatr. 2019 Jan;204:301-304.e2. doi: 10.1016/j.jpeds.2018.08.033. Epub 2018 Oct 9.

Pulse Oximeter Saturation Targeting and Oximeter Changes in the Benefits of Oxygen Saturation Targeting (BOOST)-II Australia and BOOST-II UK Oxygen Trials.

Author information

1
Neonatal Unit, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom. Electronic address: ben.stenson@luht.scot.nhs.uk.
2
NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
3
Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
4
The Royal Women's Hospital, Department of Obstetrics and Gynecology, The University of Melbourne; Murdoch Children's Research Institute Melbourne, Melbourne, Australia.
5
National Perinatal Epidemiology Unit Clinical Trials Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
6
NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Statistics, Macquarie University, Sydney, NSW, Australia.

Abstract

Infants in the Australian and UK Benefits of Oxygen Saturation Targeting-II trials treated using revised oximeters spent more time within their planned pulse oximeter saturation target ranges than infants treated using the original oximeters (P < .001). This may explain the larger mortality difference seen with revised oximeters. If so, average treatment effects from the Neonatal Oxygen Prospective Meta-analysis trials may be underestimates.

KEYWORDS:

blindness/epidemiology; blindness/etiology; cerebral palsy/epidemiology; enterocolitis, necrotizing/epidemiology; enterocolitis, necrotizing/etiology; humans; incidence; infant; infant mortality; infant, extremely premature; infant, newborn; oximetry; oxygen/administration & dosage; oxygen/adverse effects; oxygen/blood; trial

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center